R&D News | pharmaphorum

News

ASCO26: BMS hails "compelling" phase 3 celmod readout

Bristol Myers Squibb has high hopes for its celmod drugs, and a phase 3 trial for mezigdomide in multiple myeloma at ASCO26 has delivered the goods.

News

WHO names three 'priority' Ebola drugs for trials

The WHO has named drugs from Regeneron, Mapp Bio, and Gilead that should be fast-tracked through trials to respond to the current Ebola outbreak.

News

Innovent in line for $10.5bn in Pfizer cancer alliance

Pfizer has signed a strategic-level alliance with Innovent, worth $10.5bn and spanning 12 cancer assets, in another sign of China's rising R&D status.

News

GSK hails 'unprecedented' cure rates with hep B drug

The B-Well trials of GSK's bepirovirsen position the antisense drug as a "major step towards a cure for hepatitis B infection," according to experts.

News

Zuckerberg, Chan's Biohub launches protein 'world model'

Chan Zuckberg Initiative-backed Biohub has made what it says is an AI-powered "world model" of protein biology available freely to researchers.

News

Heart drug developer Kardigan files IPO

The steady stream of biotech IPOs on the Nasdaq this year has continued, with Kardigan the latest to make its intention to list known.

ASCO26: BMS hails "compelling" phase 3 celmod readout

WHO names three 'priority' Ebola drugs for trials

Innovent in line for $10.5bn in Pfizer cancer alliance

GSK hails 'unprecedented' cure rates with hep B drug

Zuckerberg, Chan's Biohub launches protein 'world model'

Heart drug developer Kardigan files IPO

On GDF-15 neutralisation and cachexia, with CatalYm

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks